The trial is expected to enroll 350 subjects and evaluate the system's safety and efficacy in the treatment of both paroxysmal and persistent atrial fibrillation.
The system is designed to provide consistent, effective therapeutic solutions during cardiac ablation procedures, the AcQBlate Force gold-tipped catheter, and the system shows physicians, in real-time, how much contact force is being applied to the heart during ablations.
Enrollment for the AcQBlate Force AF trial is expected to begin in the second half of 2021, once participating sites gain necessary institutional review board (IRB) approvals.
Price Action: AFIB shares are up 7.9% at $15.43 during the premarket session on the last check Thursday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.